- Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfrontPlus news on Alchemab, Scipher and Forte. 💉 Ipsen’s Dysport aces Phase 3 migraine trials: The biotech’s injectable neurotoxin met the primary endpoint of reducing monthly migraine days in two ...Endpoints · 18d ago↗ source
- Eli Lilly dominates first-half biotech acquisitions, with no sign of slowing downRiding on its trillion-dollar heft and successes in treating obesity, Eli Lilly has now become a force in one area where it hasn’t historically been the main player: M&A. The Indianapolis-bas…Endpoints · 18d ago↗ source
- Catalent to divest UK site; Rottendorf, Evonik announce manufacturing buildsPlus, news about RoslinCT, Novo Nordisk and more. 🇬🇧 Catalent to sell UK site to Codis: The CDMO is set to take Catalent’s oral solid dose factory in Nottingham, with ...